Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19897449 | 1.00 | S1PR5 (0.41) | S1PR5S1PR4S1PR1S1PR3SLC6A11 | |
| SCHEMBL19897466 | 1.00 | S1PR5 (0.41) | S1PR5S1PR4S1PR1S1PR3SLC6A11 | |
| SCHEMBL3934961 | 0.89 | SLC6A11 (0.50) | SLC6A11CYP1A2SLC6A1CYP2D6CYP2C9 | |
| SCHEMBL3941089 | 0.88 | KDM4E (0.42) | S1PR1SMN1; SMN2TSHRCYP2C19HSD17B10 | |
| SCHEMBL19897423 | 0.84 | S1PR5 (0.41) | S1PR5S1PR4S1PR1S1PR3SLC6A1 | |
| SCHEMBL4080259 | 0.83 | NOTUM (0.42) | S1PR5S1PR4S1PR1S1PR3SLC6A11 | |
| SCHEMBL19289676 | 0.83 | NOTUM (0.42) | S1PR5S1PR4S1PR1S1PR3SLC6A11 | |
| SCHEMBL262828 | 0.81 | SLC6A1 (0.49) | CYP1A2SLC6A1CYP2D6CYP2C9TSHR | |
| SCHEMBL3264345 | 0.78 | CYP1A2 (0.46) | S1PR5S1PR4S1PR1S1PR3CYP1A2 | |
| SCHEMBL1361559 | 0.76 | S1PR5 (0.43) | S1PR5S1PR4S1PR1S1PR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | claimed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| US-20180057486-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-03-01 | — | — | US | claimed |
| CN-101180290-B | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-12-12 | — | — | CN | claimed |
| CN-101522670-B | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-05-23 | — | — | CN | claimed |
| CN-101203503-B | Novel thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-12-28 | — | — | CN | claimed |
| CN-101627034-A | Amino-pyridine derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2010-01-13 | — | — | CN | claimed |
| CN-101522670-A | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | claimed |
| CN-101511827-A | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-19 | — | — | CN | claimed |
| CN-101203503-A | Novel thiophene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101180290-A | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-14 | — | — | CN | claimed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11613536-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-28 | — | — | US | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-20180057486-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-11613536-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.